An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of 24 weeks, and a follow-up phase of 4 weeks. Study drug will be administered via intravenous (IV) push weekly.
• Subjects have AA, meeting all of the following criteria:
⁃ Clinical diagnosis of AA with no other aetiology of hair loss ;
⁃ At least 35% scalp hair loss, as defined by a SALT score ≥ 35, at Screening and Baseline. Approximately 25% of subjects with 35% to \<50% scalp hair loss and 25% may have AT/AU.
⁃ Current episode of hair loss lasting \> 6 months to \< 7 yrs at time of Screening; and
⁃ No appreciable change in terminal hair regrowth within 6 months of the baseline visit.